NCT05304611

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of L9LS in healthy Malian children, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf) infection over a 7-month malaria season in healthy Malian children 6-10 years of age.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
365

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 28, 2022

Completed
18 days until next milestone

Study Start

First participant enrolled

March 18, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 31, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 20, 2024

Completed
3 months until next milestone

Results Posted

Study results publicly available

July 10, 2024

Completed
Last Updated

July 10, 2025

Status Verified

June 1, 2025

Enrollment Period

2.1 years

First QC Date

February 28, 2022

Results QC Date

June 12, 2024

Last Update Submit

June 23, 2025

Conditions

Outcome Measures

Primary Outcomes (12)

  • Participants With Local Adverse Events (AEs) - Year One

    Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants.

    Within 7 days after administration of L9LS

  • Severity of Local Adverse Events (AEs) - Year One

    The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death

    Within 7 days after administration of L9LS

  • Participants With Systemic Adverse Events (AEs) - Year One

    Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants.

    Within 7 days after the administration of L9LS

  • Severity of Systemic Adverse Events (AEs) - Year One

    The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death

    Within 7 days after the administration of L9LS

  • Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study

    Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by microscopic examination of thick blood smear collected from participants from day 14 through week 28 (196 days) after administration of L9LS or placebo. Analysis was done as number of participants who had at least one positive blood smear.

    Day 7 through week 28

  • Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study

    Number of participants with detectable anti-drug antibody (ADA) in sera after exposure to L9LS. Serum was collected from participants at specific timepoints throughout the study, on days 0, 7, 28, 84, 168, and 196. The tier 3 assay was used to directly measure ADA's ability to impair L9LS binding to Plasmodium falciparum circumsporozoite protein (PfCSP). Analysis was done to determine number of participants with positive or detectable ADA in sera.

    Measured through week 36

  • Maximum Total Plasma Concentration (Cmax) for L9LS - Extension Study

    Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, \& 252 after the administration of L9LS. Cmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose. Analysis was done to determine each participant's observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations.

    Measured through Week 36

  • Time to Maximum Plasma Concentration (TMax) for L9LS - Extension Study

    Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, \& 252 after the administration of L9LS. Tmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles. Analysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration.

    Measured through Week 36

  • Participants With Local Adverse Events (AEs) - Extension Study

    Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants.

    Within 7 days after administration of L9LS

  • Severity of Local Adverse Events (AEs) - Extension Study

    The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death

    Within 7 days after administration of L9LS

  • Participants With Systemic Adverse Events (AEs) - Extension Study

    Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants.

    Within 7 days after the administration of L9LS

  • Severity of Systemic Adverse Events (AEs) - Extension Study

    The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death

    Within 7 days after the administration of L9LS

Secondary Outcomes (7)

  • Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR)

    Measured through week 24 (dose escalation study) and week 28 (efficacy study)

  • Participants With Clinical Malaria - Pediatric Dose Escalation Study

    Measured through Week 28

  • Participants With Clinical Malaria - Pediatric Efficacy Study

    Measured through Week 28

  • Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study

    Measured through Week 28

  • Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study

    Measured through Week 24

  • +2 more secondary outcomes

Study Arms (12)

Adult Dose-escalation study: Arm 1: 300 mg of L9LS

EXPERIMENTAL

Adult participants receive single dose of 300 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 2.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Adult Dose-escalation study: Arm 2: 600 mg of L9LS

EXPERIMENTAL

Adult participants receive single dose of 600 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 3.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS

EXPERIMENTAL

Adult participants receive highest single dose of 20 mg/kg IV of L9LS intravenously. Once subjects reach day 7 post-administration without safety concerns dosing begins for pediatric subjects dose escalation arm 1.

Biological: L9LS (VRC-MALMAB0114-00-AB) intravenous injection

Pediatric Dose-escalation study: Arm 1: 150 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 years receive single dose of 150 mg L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for arm 2.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Dose-escalation study: Arm 2: 300 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 years receive single dose of 300 mg L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for the pediatric efficacy study arms.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Dose-escalation study: Arm 3: Placebo

PLACEBO COMPARATOR

Pediatric subjects ages 6-10 receive single dose placebo of normal saline subcutaneously for comparison.

Other: Placebo

Pediatric Efficacy study: Arm 1: 150 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 receive single dose of 150 mg L9LS subcutaneously.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Efficacy study: Arm 2: 300 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 receive single dose of 300 mg L9LS subcutaneously.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Efficacy study: Arm 3: Placebo

PLACEBO COMPARATOR

Pediatric subjects ages 6-10 receive single dose placebo of normal saline subcutaneously.

Other: Placebo

Pediatric Extension study: Arm 1: 150 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 who completed year one of the study and agreed to continue with the extension were randomized to receive 150 mg of L9LS subcutaneously.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Extension study: Arm 2: 300 mg of L9LS

EXPERIMENTAL

Pediatric subjects ages 6-10 who completed year one of the study and agreed to continue with the extension were randomized to receive 300 mg of L9LS subcutaneously.

Biological: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection

Pediatric Extension study: Arm 3: Placebo

PLACEBO COMPARATOR

Pediatric subjects ages 6-10 who completed year one of the study and agreed to continue with the extension were randomized to receive placebo of normal saline subcutaneously.

Other: Placebo

Interventions

Administered one time via subcutaneous route.

Adult Dose-escalation study: Arm 1: 300 mg of L9LSAdult Dose-escalation study: Arm 2: 600 mg of L9LSPediatric Dose-escalation study: Arm 1: 150 mg of L9LSPediatric Dose-escalation study: Arm 2: 300 mg of L9LSPediatric Efficacy study: Arm 1: 150 mg of L9LSPediatric Efficacy study: Arm 2: 300 mg of L9LSPediatric Extension study: Arm 1: 150 mg of L9LSPediatric Extension study: Arm 2: 300 mg of L9LS

Administered one time via intravenous route.

Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS
PlaceboOTHER

Normal saline administered one time via subcutaneous route.

Pediatric Dose-escalation study: Arm 3: PlaceboPediatric Efficacy study: Arm 3: PlaceboPediatric Extension study: Arm 3: Placebo

Eligibility Criteria

Age6 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Is within the appropriate age range for the respective cohort:
  • Children: Aged ≥6 years and \<11 years.
  • Adults: Aged ≥18 years.
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
  • In good general health and without clinically significant medical history.
  • Adult participants or parent and/or guardian of minor participants able to provide informed consent.
  • Willing to have blood samples and data stored for future research.
  • Resides in or near Kalifabougou or Torodo, Mali, and available for the duration of the study.
  • For the adult cohort, females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.
  • Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
  • Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have urine or serum pregnancy test performed per protocol.
  • Participated in the first year of the protocol.
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
  • In good general health and without clinically significant medical history.
  • Parent and/or guardian able to provide informed consent.
  • +2 more criteria

You may not qualify if:

  • Body weight \<15 kg or \>30 kg for children, or \>60 kg for adults.
  • Currently receiving or planning to receive seasonal malaria chemoprevention (SMC).
  • Any history of menses (for 6-10 year old cohort) or positive pregnancy test at screening (for adult cohort).
  • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol.
  • Subject (for adult subjects) or parental (for minor subjects) study comprehension examination score of \<80% correct or per investigator discretion.
  • Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
  • Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
  • Infected with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
  • Clinically significant abnormal electrocardiogram (ECG; Corrected QT Interval (QTc) \>460 or other significant abnormal findings, including unexplained tachycardia or bradycardia).
  • Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
  • Receipt of any investigational product within the past 30 days.
  • Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
  • History of a severe allergic reaction or anaphylaxis.
  • Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
  • Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
  • +34 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Kalifabougou MRTC Clinic

Kalifabougou, Koulikoro, Mali

Location

Torodo MRTC Clinic

Torodo, Koulikoro, Mali

Location

Related Publications (1)

  • Kayentao K, Ongoiba A, Preston AC, Healy SA, Hu Z, Skinner J, Doumbo S, Wang J, Cisse H, Doumtabe D, Traore A, Traore H, Djiguiba A, Li S, Peterson ME, Telscher S, Idris AH, Adams WC, McDermott AB, Narpala S, Lin BC, Serebryannyy L, Hickman SP, McDougal AJ, Vazquez S, Reiber M, Stein JA, Gall JG, Carlton K, Schwabl P, Traore S, Keita M, Zeguime A, Ouattara A, Doucoure M, Dolo A, Murphy SC, Neafsey DE, Portugal S, Djimde A, Traore B, Seder RA, Crompton PD; Mali Malaria mAb Trial Team. Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria. N Engl J Med. 2024 May 2;390(17):1549-1559. doi: 10.1056/NEJMoa2312775. Epub 2024 Apr 26.

MeSH Terms

Conditions

Malaria

Interventions

Injections, SubcutaneousInjections, Intravenous

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Intervention Hierarchy (Ancestors)

InjectionsDrug Administration RoutesDrug TherapyTherapeuticsAdministration, Intravenous

Results Point of Contact

Title
Dr. Peter Crompton
Organization
National Institute of Allergy and Infectious Diseases (NIAID)

Study Officials

  • Kassoum Kayentao, MD, MPH, PhD

    Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS)

    PRINCIPAL INVESTIGATOR
  • Peter Crompton, MD, MPH

    National Institutes of Health (NIH)

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
SEQUENTIAL
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2022

First Posted

March 31, 2022

Study Start

March 18, 2022

Primary Completion

April 20, 2024

Study Completion

April 20, 2024

Last Updated

July 10, 2025

Results First Posted

July 10, 2024

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Human data generated in this study for future research will be shared as follows: * De-identified or identified data with approved outside collaborators under appropriate agreements. * De-identified results or data in publication and/or public presentations.

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be shared at the time of publication or shortly thereafter.
Access Criteria
Data from this study may be requested from other researchers indefinitely after the completion of the primary endpoint by contacting Laboratory of Immunogenetics at NIH

Locations